Trial Profile
An Open-label, Randomized, Controlled, Multicenter, Phase I/II Trial Investigating 2 EMD 525797 Doses in Combination With Cetuximab and Irinotecan Versus Cetuximab and Irinotecan Alone, as Second-line Treatment for Subjects With K-ras Wild Type Metastatic Colorectal Cancer (mCRC)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Abituzumab (Primary) ; Cetuximab; Irinotecan
- Indications Carcinoma; Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms POSEIDON
- Sponsors Merck KGaA; Merck Sharp & Dohme
- 08 Oct 2018 According to a Merck KGaA media release, data from this study will be presented at the European Society for Medical Oncology Annual Meeting (ESMO) 2018 Congress.
- 29 Mar 2016 Number of treatment arms changed from 3 to 7, as reported by ClinicalTrials.gov record.
- 29 Mar 2016 Status changed from discontinued to completed, according to ClinicalTrials.gov record.